TITLE: "Association between COVID-19 vaccination, infection, and risk of Guillain-Barre syndrome, Bell's palsy, encephalomyelitis and transverse myelitis: a population-based cohort and self-controlled case series analysis"

AUTHORS: Xintong Li, doctoral student*1, Eugenia Martinez-Hernandez, physician-researcher*2, Elena Roel Herranz^{3,4}, Antonella Delmestri, senior health data scientist¹, Talita Duarte-Salles, epidemiologist³, Victoria Strauss, lead statistician*1, Edward Burn**1,3, and Daniel Prieto-Alhambra, professor**1,5

- 1. Centre for Statistics in Medicine, NDORMS, University of Oxford, Oxford, UK
- Neurology Department, Hospital Clinic de Barcelona and University of Barcelona, Barcelona, Spain
- 3. Fundacio Institut Universitari per a la recerca a l'Atencio Primaria de Salut Jordi Gol i Gurina (IDIAPJGol), Barcelona, Spain
- Universitat Autònoma de Barcelona, Bellaterra (Cerdanyola del Vallès), Barcelona,
 Spain
- Department of Medical Informatics, Erasmus University Medical Center, Rotterdam, Netherlands

CORRESPONDING AUTHOR

Dr Victoria Strauss, Lead statistician
ORCID ID: 0000-0002-5172-512X
Centre for Statistics in Medicine, NDORMS, University of Oxford
Botnar Research Centre, Windmill Road, OX37LD, Oxford, United Kingdom

^{*} joint first authors

^{**} joint senior authors

ABSTRACT [306 / 300w]

OBJECTIVE

We aimed to study the association between COVID-19 vaccines, SARS-CoV-2 infection, and the risk of immune-mediated neurological events.

METHODS

Design

Population-based historical rate comparison study and self-controlled case series (SCCS) analysis.

Setting

Primary care records from the United Kingdom.

Participants

Individuals who received the first dose of ChAdOx1 or BNT162b2 between 8 December 2020 and 6 March 2021. A cohort with a first positive RT-PCR test for SARS-CoV-2 between 1 September 2020 and 28 February 2021 was used for comparison.

Main outcome measures

Outcomes included Guillain-Barre syndrome (GBS), Bell's palsy, encephalomyelitis, and transverse myelitis.

Incidence rates were estimated in the 28 days post first-dose vaccine, 90 days post-COVID-19, and between 2017 to 2019 for the general population cohort for background rates. Indirectly standardised incidence ratios (SIRs) were estimated. Adjusted incidence rate ratios (IRR) were estimated from the SCCS when sufficient statistical power was reached.

Results

We included 1,868,767 ChAdOx1 and 1,661,139 BNT162b2 vaccinees; 299,311 people infected with COVID-19; and 2,290,537 from the general population. SIRs for GBS were 1.91 [95% CI: 0.86 to 4.26] after ChAdOx1, 1.29 [0.49 to 3.45] after BNT162b2, and 5.20 [1.95 to 13.85] after COVID-19. In the same cohorts, SIRs for Bell's palsy were 1.34 [1.05 to 1.72], 1.15 [0.88 to 1.50], and 1.23 [0.80 to 1.89], and for encephalomyelitis 1.62 [0.61 to 4.31], 0.86 [0.22 to 3.46], and 11.05 [5.27 to 23.17], respectively. Transverse myelitis was too rare to analyse (n<5 in all cohorts). SCCS analysis was only conducted for Bell's palsy due to limited statistical power. We found no association between either vaccine and Bell's palsy, with an IRR of 1.10 [0.81 to 1.46] and 1.15 [0.87 to 1.49] for BNT162b2 and ChAdOx1, respectively.

Conclusions

We found no consistent association between either vaccine and any of the studied neuroimmune adverse events studied. Conversely, we found a 5-fold increase in risk of GBS and an 11-fold of encephalomyelitis following COVID-19.

MAIN TEXT [3177words]

INTRODUCTION

As of 3 September 2021, the COVID-19 pandemic has caused more than 4.5 million deaths worldwide. After rapid development, 5.2 billion vaccine doses against SARS-CoV-2 have been administered through national vaccination programs.[1] The AstraZeneca (ChAdOx1) and Pfitzer-BioNTech (BNT162b2) vaccines were the first to be approved for use in the United Kingdom in December 2020. They have shown high effectiveness in preventing severe COVID-19 in clinical trials and real-world settings.[2–4] Over 91 million doses of the vaccine have been administered in the UK, and 43 million people have been fully vaccinated, which is 79% of the population.[5] As immunisation programs continue to advance, safety monitoring is crucial to assess adverse events and identify potential risks.

Immune-mediated neurological disorders among individuals vaccinated with adenovirus-based vaccines against SARS-CoV-2 have been identified. Up to 25 August, the Medicines and Healthcare products Regulatory Agency (MHRA) has received 393 reports of Guillain-Barré syndrome (GBS) and 23 reports of Miller-Fisher syndrome (a variant of this disease) after ChAdOx1, 44reports of GBS after BNT162b2, and 3 reports of GBS after the Moderna (mRNA-1273) vaccine, [6] Instances of these and other neuro-immune events also have been reported elsewhere. Reports after ChAdOx1 include seven cases of GBS in India,[7] two in the UK,[8,9] one in each of in France, [10] Italy, [11] and Malta, [12] and nine cases of bifacial weakness with paresthesias, a variant of GBS, in the UK,[13,14] and one in Italy,[15] and two cases of sensory GBS in Korea.[16] Three cases of acute transverse myelitis were reported during the clinical trials for ChAdOx1,[17,18] two in case studies,[19,20] and one report of longitudinal extensive transverse myelitis after ChAdOx1 vaccination reported in a case study.[21] Reports after the BNT162b2 vaccine include one case of GBS in each of the United States (US) and Qatar,[22,23] two in Italy,[24,25] and seven among a cohort of 3,89 million vaccinees in Mexico,[26] and one case of acute disseminated encephalomyelitis.[27] Data from the BNT162b2 and mRNA-1273vaccines trials also suggested a possible association with Bell's palsy, with seven cases in the active arms compared with one case in the placebo arms of the trials, and six subsequent reports.[28-33] The clinical trial of the Johnson & Johnson viral vector vaccine Ad26.COV2.S reported one case of GBS in each of the placebo and active trial arms 10 days after the injection.[34,35] There were 2 reports of the GBS variant with bifacial weakness in the US,[26,36] and a warning of the US Food and Drug Administration about the Ad26.COV2.S vaccine and rare but serious cases of GBS.[37] One case of Bell's palsy and one of transverse myelitis with Bell's palsy reported after Ad26.COV2.S vaccination

Although these reports do not imply causality, the temporal association between vaccination and neurological symptoms warrants robust post-vaccination surveillance. Large-scale epidemiologic studies are required to determine whether COVID-19 vaccination increases the risks above background rates in the general population.

We leveraged large routinely collected datasets including millions of vaccinated people in the UK to study the potential association between COVID-19 vaccination and the risk of developing GBS, Bell's palsy, encephalomyelitis, and transverse myelitis. To help contextualise our results, we also studied the associations between infection with SARS-CoV-2 and the risk of the studied immune-mediated neurological outcomes.

METHODS

Data sources

Data were obtained from the UK Clinical Practice Research Datalink (CPRD) GOLD and the CPRD Aurum. CPRD GOLD and CPRD Aurum contain routinely collected data from primary care practices in the UK,[38,39] representing 5% and 20% of the current UK population, respectively.[40,41] Both databases have been mapped to the Observational Medical Outcomes Partnership (OMOP) common data model for curation and analysis.[42]

Study participants

The populations of interest were individuals who had received their first dose of a COVID-19 vaccine and people infected with SARS-CoV-2, as identified from CPRD AURUM. Using the CPRD GOLD data, we created a background population cohort. The two CPRD databases were used because the CPRD GOLD data was only available until mid-2020..

Two mutually exclusive cohorts were constructed of people vaccinated with first-dose ChAdOx1 or BNT162b2 between 8 December 2020 and 6 March 2021. The date of the first vaccine dose administration was used as the index date. The SARS-Cov-2-infected cohort included people with a first positive RT-PCR test between 1 September 2020 and 28 February 2021, with the test date used as the index date. The background population cohort were people with a primary care contact recorded between 1 January 2017 and 31 December 2019. The index date for the general population cohort was the first visit date during this period.

All participants were required to be aged 30 years or older and to have at least 365 days of visibility in the data before the index date. For each cohort, participants were censored at the first of a health outcome of interest, end of data availability (14 March 2021), or leaving the database (death or migration).

Events of interest

The events of interest were four immune-mediated neurological disorders prespecified as potential adverse events of special interest for COVID-19 vaccine safety: Guillain-Barré syndrome, Bell's palsy, encephalomyelitis, and transverse myelitis.[43] Events were identified using previously validated clinical codes from electronic health records.[43] Details of the Systematized Nomenclature of Medicine (SNOMED) codes used to define the outcomes are available in Appendix Table 1.

Study design

We used the historical rate comparison method. Incidence rates of each outcome in the vaccinated cohorts and SARS-Cov-2-infected cohort were used as "observed" rates and compared with the "expected" background incidence rates estimated from the general population cohort. For the vaccinated cohorts, we estimated the rates during the 1 to 28 days after the first-dose vaccination (day 0). A 90-days post-test period was used for the SARS-Cov-2-infected cohort.

A self-controlled case series (SCCS) method was then applied where possible to minimise confounding. SCCS is an established method for vaccine safety surveillance, which includes only individuals experiencing both exposure and outcome, and participants act as controls for themselves, therefore eliminating time-fixed confounding.[44] Within-person comparisons of event rates were made between the pre-vaccination (baseline) and the post-vaccine exposure period. Similar to the historical rate comparison design, we defined the exposure window as the 1 to 28 days after first-dose vaccination (day 0). The study period of the SCCS analysis is from 1st January 2017 to the end of data availability. (Figure 2)

We also estimated the 28-days pre-vaccination window separately since an event in that period may change the likelihood of receiving the vaccine.[44,45]

Statistical analysis

We characterised the study participants in each cohort in terms of socio-demographics (e.g., age, sex), comorbidities (any time before vaccination), and recent medication use during the 6 months before the index date. We estimated the observed rates during the 28 days post-immunization and 90 days post-test period for the vaccinated and SARS-Cov-2 infected cohorts, respectively. Similarly, background rates were estimated for the general population in 2017–2019, stratified by age and sex. We calculated crude incidence rates as the total number of events divided by the person-time at risk per 100,000 person-years. We used indirect standardisation to account for differences between the age-sex structure of the vaccinated or SARS-CoV-2 cohorts and the general population.[46] We calculated standardised incidence rate ratios (SIRs) and 95% confidence intervals (CIs) to compare observed and expected rates. The number needed to harm (NNH) were calculated for each cohort as well.[47]

We applied two further sensitivity analyses to check the impact of our design choices. We replicated the analyses after removing the 1-year prior observation requirement. We also recalculated background rates using a background population cohort of all participants followed from 1 January 2017 instead of using their first healthcare visit date as the index date.

In addition, a SCCS was conducted for any identified signals to minimise confounding by indication. Since individuals serve as their own controls, both measured and unmeasured time-fixed confounding are controlled by design. We included age (as 5-years band) and seasonality (four seasons) to adjust for time-varying confounding. Conditional Poisson regression models were fitted to estimate incidence rate ratio (IRR) and 95% confidence intervals for each outcome according to exposure window,[48] comparing post- vs pre-vaccine time. Due to the limited number of events, we only had power to run SCCS for Bell's Palsy (Appendix table 2).[49]

Any subgroups with less than 5 people were blinded and reported as <5, following information governance requirements. The study was approved by the Independent Scientific Advisory Committee (ISAC 20_000211). SCCS were run using the self-controlled case series package in R.[50] Our analytical code is available for review and replication of our findings at https://github.com/oxford-pharmacoepi/CovidVaccinationSafetyStudy_neuroimmune.

Patient and public involvement

No patients or members of the public were directly involved in the design or analysis of the reported data. The Independent Scientific Advisory Committee responsible for the approval of our protocol involved patients in the evaluation of our data access application.

RESULTS

We included 1.9 million people vaccinated with first-dose ChadOx1, 1.7 million vaccinated with first-dose BNT162b2, 299,311 infected with SARS-CoV-2, and 2.3 million general population participants. Both vaccinated cohorts were older (average age 66 and 67 years, respectively) than those infected with SARS-CoV-2 (average age 48 years) and the general population (average age 54 years). Vaccinated participants had a higher prevalence of comorbidities, including cancer, diabetes, and other long-term conditions comparing with the general population (see Table 1). The prevalence of use of systemic corticosteroids and anticoagulants/antithrombotics was also higher in the vaccinated cohorts than the infected cohort, but was similar to the general population used for estimating background rates.

Among 1,867,708 ChAdOx1 vaccinees, we observed 64 cases of Bell's palsy during the 28 days following vaccination and expected 48 events after standardisation, resulting in an SIR of 1.34 [1.05 to 1.72] (Table 2) and a number needed to harm (NNH) of 113,885. Equivalent figures for BNT162b2 were 54 observed and 47 expected among 1,660,289 participants, with a non-significant SIR of 1.15 [0.88 to 1.50]. Among 299,069 infected with SARS-CoV-2, we observed 21 events in the 90 days following a first positive PCR test and expected 17 events, equivalent to an SIR of 1.23 [0.80 to 1.89]. (Figure 2) The SCCS analysis showed adjusted IRR of 1.15 [0.87 to 1.49] for ChAdOx1, IRR of 1.10 [0.81 to 1.46] for BNT162b2, and IRR of 0.98 [0.61 to 1.52] for SARS-CoV-2 infection (Table 3).

Among 1,868,598 people vaccinated with ChAdOx1, 6 GBS events were observed and 3 expected, resulting in a non-significant SIR of 1.91 [0.86 to 4.26]. Among 1,661,011 people receiving BNT162b2, <5 GBS events were observed and 3 expected, resulting in an SIR of 1.29 [0.49 to 3.45]. In contrast, <5 GBS events were observed in 299,196 participants infected with SARS-CoV-2 and <1 expected, resulting in an SIR of 5.20 [1.95 to 13.85].

Sensitivity analyses were in line with these results. The main additional finding was a significant SIR for GBS following ChAdOx1 vaccination when we removed the 1-year washout and the requirement for a healthcare visit in the background population. We then observed 7 events in 1,868,598 participants and expected 3 events, resulting in an SIR of 2.20 [1.05 to 4.61], equivalent to an NNH of 514,773. No association was seen for BNT162b2. The sensitivity analysis had similar results to the main analysis for the cohort infected with SARS-CoV-2, with an SIR of 5.66 [2.12 to 15.07] and an NNH of 90,703. (Table 4)

Fewer than 5 events of encephalomyelitis were seen following ChAdOx1 and BNT162b2, with equivalent SIRs of 1.62 [0.61 to 4.31] and 0.86 [0.22 to 3.46], respectively. Seven encephalomyelitis events were observed and <1 expected following SARS-CoV-2 infection in 299,201 participants, equating to an SIR of 11.05 [5.27 to 23.17], and an NNH of 46,750. All sensitivity analyses were in line with these results.

Transverse myelitis was very rare in all three cohorts, with <5 events observed and expected in the vaccinated and infected cohorts. Equivalent adjusted SIRs were 2.27 [0.73 to 7.02] in the

ChAdOx1 cohort, 2.26 [0.73 to 7.01] in the BNT162b2 cohort, and 1.71 [0.24 to 12.15] in the infected cohort. Sensitivity analyses were consistent with these results.

DISCUSSION

Key findings

This is the largest cohort study to date on the neuro-immune safety of COVID-19 vaccines, including 1.9 million ChAdOx1 and 1.7 million BNT162b2 vaccine recipients. Our primary analyses with a historical rates comparison method found a potential association between ChAdOx1 and the risk of developing Bell's palsy, with an estimated 30% relative increase in risk. If causal, this signal would equate to one Bell's palsy event per 110,000 people receiving this vaccine. No associations were found with the BNT162b2 vaccine or SARS-CoV-2 infection. A SCCS to minimise patient-level confounding showed no statistically significant association between either vaccine and Bell's palsy. As we observed differences in baseline characteristics between vaccine recipients and the background population, our findings could be related to residual confounding rather than a causal link.

We analysed a cohort of almost 300,000 people infected with the virus these vaccines prevent, SARS-CoV-2. We demonstrated a striking association between COVID-19 and two severe immune-mediated neurological outcomes: a 5-fold increased risk of GBS and an 11-fold excess risk of encephalomyelitis. These findings provide a useful counterfactual for vaccination and strengthen the risk-benefit of achieving immunity against COVID-19 through vaccination rather than infection.

Findings in context

Neuro-immune disorders have been identified as adverse events of special interest by regulators, such as the FDA in the US and EMA in Europe, and organisations such as the Brighton Collaboration. They have been closely monitored during immunisation campaigns.[43,51,52] Although phase 3 clinical trials of mRNA vaccines noted an imbalance of Bell's palsy cases in vaccine and placebo groups, there was insufficient power to draw causal associations.[2,53]

More recently, case reports and case series have reported immune-mediated neurological disorders after COVID-19 vaccines, such as facial nerve palsies after mRNA Covid-19 vaccines[54] and cases of GBS after adenovirus-based vaccines, including ChAdOx1.[7–9,13] On 13 July 2021, the FDA updated the label of the Johnson & Johnson adenovirus-based COVID-19 vaccine to include a warning about the potential risk of GBS following vaccination.[55]

The product information for the ChAdOx1 vaccine has also included a warning that Guillain-Barré syndrome (GBS) has very rarely followed vaccination.[37] However, there is currently not enough data on the safety of vaccines for people with these conditions. Conversely, the UK MHRA stated on 16 July 2021 that the number of reports of Bell's palsy from the spontaneous report system is similar to the expected rate and that there is no increased risk following any vaccine based on current evidence.[6]

Real-world studies have also assessed the association between facial nerve palsy. SARS-CoV-2 infection and COVID-19 vaccines. One study using electronic medical records data from 41 healthcare organisations worldwide found that 0.08% of patients had a diagnosis of Bell's palsy within 8 weeks after being diagnosed with COVID-19, of whom 53.9% had no history of Bell's palsy, and a higher risk in patients with COVID-19 compared with those vaccinated. However, they did not calculate the comparative risk of Bell's palsy between COVID-19 vaccination and the general population.[56] A case-control study from Israel analysed emergency department admission data and found no increased risk of facial nerve palsy after BNT162b2 vaccination. They also compared the numbers of cases in January and February 2021 to the same period during 2015 to 2020, and found no meaningful increase in admission numbers due to facial nerve palsy.[57] Renoud et al. conducted a disproportionality analysis using the World Health Organization's pharmacovigilance database. They found no higher safety signal for facial palsy after mRNA Covid-19 vaccines when compared with all other viral vaccines or restricted to influenza vaccines.[58] Eric Wan et al. found an overall increased risk of Bell's palsy after vaccinated with CoronaVac, an inactivated virus COVID-19 vaccine, but no increased risk after BNT162b2 vaccination.[59] In our study, we found no elevated risk of Bell's palsy with BNT162b2, but a small increased risk with ChAdOx1. Yet the association was not proved in the SCCS analysis where confounding was addressed.

Although cases of neuro-immune disorders after SARS-CoV-2 infection have been reported, [60–63] causality remains unclear. Single cases of GBS and small series, mainly from Europe and including all phenotypic variants, were reported and postulated a possible post-infectious mechanism. [64–66] Multicentric studies in Spain and Italy during the beginning of the pandemic reported a higher frequency of GBS among patients with COVID-19 than those without COVID-19, or compared with the incidence in the same months of 2019. [67,68] However, one study compared reported cases in 2020 and 2016–2019 in the England National Immunoglobulin Database and found no significant association between COVID-19 and GBS. [69] Another study reported a 7-fold risk of Bell's palsy among patients with COVID-19 compared with individuals who received COVID-19 vaccines. [56] Recent studies have evaluated reports of acute disseminated encephalomyelitis and acute haemorrhagic leukoencephalitis and identified more than 45 cases up to May-June, 2021 associated with SARS-CoV-2 infection and with poor neurologic outcomes. [70,71] Our study found an 11-fold increased risk for encephalomyelitis and 5-fold for GBS after SARS-CoV-2 infection, with no elevated risk for Bell's palsy or transverse myelitis.

Study strengths and limitations

The main strength of our study is the population-based method with data from the UK primary care system, which have great representativeness and complete capture of vaccinations among the UK population. In addition, the use of self-controlled case series study design took the advantage of within person comparison to reduce time-fixed confounding. We also further adjusted for age and seasonality to control for time-varying confounding.

Our study has limitations. As we only included primary care data, diagnoses from inpatient settings may not be captured and the absolute risk may be underestimated. However, a previous study has showed that CPRD primary care data captures immune-mediated neurological disorders like GBS accurately, even without linking hospital data.[72] Within-database comparisons are recommended when comparing observed and expected rates due to database-level heterogeneity.[43] We used CPRD Aurum and CPRD GOLD. Although both contain UK primary care data, these data come from different electronic health record clinical systems and use different medical coding. However, one study showed that the two databases generated similar estimates.[73] We used code lists and algorithms for the identification of neuro-immune events previously published as part of a study on the background rates of COVID-19 AESI.[43] Mapping to the OMOP common data model also helped maximise comparability. The short follow-up time after vaccination may have led to underreporting of events of interest.

The background rate comparison method has been shown to be a sensitive but not specific method, with a high type 1 error.[74] Although we adjusted for age and sex by indirect standardisation and anchored the background incidence rates on a health visit or contact as recommended, the analysis may still have overestimated the risk. Our SCCS analyses provide further reassurance, as they account for all time-fixed confounding by using the same person as a "control" .[44]

Conclusion

We found no consistent risk of any of the studied neuro-immune events with either vaccine. Conversely, we found a 5-fold increase in risk of GBS and an 11-fold risk of encephalomyelitis following COVID-19 infection. Our data illustrate that SARS-CoV-2 infection, and not COVID-19 vaccines, is associated with an increased risk of neuro-immune outcomes.

Ethical approval

The protocol for this research was approved by the independent scientific advisory committee for Medicine and Healthcare products Regulatory Agency database research (protocol number 20_000211)

Data availability statement

Patient level data cannot be shared without approval from data custodians owing to local information governance and data protection regulations. Aggregated data, analytical code, and detailed definitions of algorithms for identifying the events are available in a GitHub repository (https://github.com/oxford-pharmacoepi/CovidVaccinationSafetyStudy_neuroimmune).

Acknowledgments

We thank Jennifer A de Beyer (Centre for Statistics in Medicine, University of Oxford) for English language editing.

Funding: This work was partially funded by the UK National Institute for Health Research (NIHR), and European Health Data and Evidence Network (EHDEN). EHDEN has received funding from the Innovative Medicines Initiative 2 Joint Undertaking under grant agreement No 806968. The Innovative Medicines Initiative 2 Joint Undertaking receives support from the European Union's Horizon 2020 research and innovation programme and EFPIA. The study funders had no role in the conceptualisation, design, data collection, analysis, decision to publish, or preparation of the manuscript.

Contributors: XL and EMH are joint first authors. XL, DAP, EB and VS conceived the study and contributed to the study design. XL, VS, and DAP interpreted the results and wrote the manuscript. All coauthors contributed to writing the manuscript. All authors approved the final version and had final responsibility for the decision to submit for publication.

Competing interests: All authors have completed the ICMJE disclosure form at http://www.icmje.org/disclosure-of-interest/ and declare the following interests: DPA receives funding from the UK National Institute for Health Research (NIHR) in the form of a senior research fellowship and the Oxford NIHR Biomedical Research Centre. XL receives the Clarendon Fund and Brasenose College Scholarship (University of Oxford) to support her DPhil study. DPA's research group has received research grants from the European Medicines Agency; the Innovative Medicines Initiative; Amgen, Chiesi, and UCB Biopharma; and consultancy or speaker fees from Astellas, Amgen, and UCB Biopharma.

The lead authors (XL and EMH) affirm that this manuscript is an honest, accurate, and transparent account of the study being reported; that no important aspects of the study have been omitted; and that any discrepancies from the study as planned (and, if relevant, registered) have been explained.

Dissemination to participants and related patient and public communities: We will disseminate a lay summary of our findings through our Twitter and other social media accounts.

TABLES AND FIGURES

Table 1. Baseline characteristics of the background population, those vaccinated with BNT162b2, those vaccinated with ChAdOx1, and those infected with SARS-CoV-2.

	General population	Vaccinated with ChadOx1	Vaccinated with BNT162b2	Infected with SARS-CoV-2
N	2,290,537	1,868,767	1,661,139	299,311
Age (median [IQR])	54 [43 to 67]	66 [56 to 73]	67 [54 to 78]	48 [39 to 58]
Sex: Male	1,094,911 (47.8%)	845,908 (45.3%)	702,863 (42.3%)	136,301 (45.5%)
Years of prior observation time (median [IQR])	13.5 [8.1 to 16.3]	19.0 [7.7 to 31.1]	19.1 [7.8 to 31.2]	12.4 [5.3 to 23.9]
Comorbidities				
Autoimmune disease	57,773 (2.5%)	72,119 (3.9%)	64,311 (3.9%)	7,136 (2.4%)
Malignancy	187,499 (8.2%)	257,449 (13.8%)	268,655 (16.2%)	15,663 (5.2%)
Diabetes mellitus	197,619 (8.6%)	306,944 (16.4%)	276,194 (16.6%)	28,488 (9.5%)
Obesity	94,054 (4.1%)	120,052 (6.4%)	98,900 (6.0%)	16,791 (5.6%)
Heart disease	251,708 (11.0%)	334,469 (17.9%)	349,669 (21.0%)	24,511 (8.2%)

Renal impairment	161,596 (7.1%)	207,751 (11.1%)	234,386 (14.1%)	14,150 (4.7%)	
Medication use (183 days prior to 4 days prior)					
Systemic corticosteroids	263,488 (11.5%)	119,766 (6.4%)	105,977 (6.4%)	14,168 (4.7%)	
Antithrombotic and anticoagulant therapies	102,605 (4.5%)	61,322 (3.3%)	65,237 (3.9%)	3,885 (1.3%)	

Table 2. Association between COVID-19 vaccination or infection and the occurrence of neuro-immune adverse events of special interest

Outcome	Population	N	Person- years-at-risk	N observed	N expecte d	SIR	NNH
Bell's palsy	Vaccinated with ChAdOx1	1,867,708	119,078	64	47.6	1.34 (1.05 to 1.72)	113885
	Vaccinated with BNT162b2	1,660,289	118,593	54	47	1.15 (0.88 to 1.50)	237184
	SARS-CoV-2 PCR positive test	299,069	40,573	21	17	1.23 (0.80 to 1.89)	74767
Encephalomyelitis	Vaccinated with ChAdOx1	1,868,554	119,134	<5	2.5	1.62 (0.61 to 4.31)	1245703
	Vaccinated with BNT162b2	1,661,019	118,646	<5	2.3	0.86 (0.22 to 3.46)	- 5536730
	SARS-CoV-2 PCR positive test	299,201	40,596	7	0.6	11.05 (5.27 to 23.17)	46750
Guillain-Barre syndrome	Vaccinated with ChAdOx1	1,868,598	119,136	6	3.1	1.91 (0.86 to 4.26)	644344
	Vaccinated with BNT162b2	1,661,011	118,645	<5	3.1	1.29 (0.49 to 3.45)	1845568
	SARS-CoV-2 PCR positive test	299,196	40,595	<5	0.8	5.20 (1.95 to 13.85)	93499
Transverse myelitis	Vaccinated with ChAdOx1	1,868,613	119,138	<5	1.3	2.27 (0.73 to 7.02)	1099184
	Vaccinated with BNT162b2	1,661,035	118,647	<5	1.3	2.26 (0.73 to 7.01)	977079
	SARS-CoV-2 PCR positive test	299,203	40,596	<5	0.6	1.71 (0.24 to 12.15)	748008

SIR: standardised incidence ratio, NNH: number needed to harm

Table 3. Incidence rate ratios (95% confidence intervals) for COVID-19 vaccination or infection and the occurrence of Bell's Palsy.

Time period	BNT162b2		ChAdOx1		SARS-CoV-2 PCR positive test	
					Number of	
	Number of events	IRR	Number of events	IRR	events	IRR
Baseline	2918	Ref	3393	Ref	662	Ref
				1.04 (0.80 to		1.10 (0.60 to
-28 to −1 days pre-exposure	57	1.13 (0.85 to 1.47)	65	1.34)	14	1.84)
				1.15 (0.87 to		
1-28 days post vaccination	50	1.10 (0.81 to 1.46)	58	1.49)	-	-
1-90 days post SARS-CoV-2						0.98 (0.61 to
infection	-	-	-	-	23	1.52)

IRR: Incidence rate ratio

Figure 1. Self-controlled case series analysis design




Figure 2. Expected vs observed rates of neuro-immune adverse events of special interest and standardised incidence ratios (SIRs)




Table 4. Sensitivity analyses

Outcome	Population	N	Person- years-at- risk	N observed	N expected	SIR	NNH
Requiring 365 days	observation, background po	pulation c	ohort of all p	participants follo	wed from 1 Jan	uary 2017	
Bell's palsy	Vaccinated with ChAdOx1	1,867,7 08	119,078	64	44.7	1.43 (1.12 to 1.83)	96772
Bell's palsy	Vaccinated with BNT162b2	1,660,2 89	118,593	54	43.7	1.24 (0.95 to 1.61)	161193
Bell's palsy	SARS-CoV-2 PCR positive test	299,069	40,573	21	15.2	1.39 (0.90 to 2.13)	51564
Encephalomyelitis	Vaccinated with ChAdOx1	1,868,5 54	119,134	<5	2.3	1.72 (0.65 to 4.59)	1099149
Encephalomyelitis	Vaccinated with BNT162b2	1,661,0 19	118,646	<5	2.1	0.93 (0.23 to 3.73)	-16610190
Encephalomyelitis	SARS-CoV-2 PCR positive test	299,201	40,596	<5	0.6	12.63 (6.02 to 26.49)	46750
Guillain Barre syndrome	Vaccinated with ChAdOx1	1,868,5 98	119,136	6	3	1.98 (0.89 to 4.42)	622866
Guillain Barre syndrome	Vaccinated with BNT162b2	1,661,0 11	118,645	<5	2.9	1.37 (0.51 to 3.64)	1510010
Guillain Barre syndrome	SARS-CoV-2 PCR positive test	299,196	40,595	<5	0.7	5.84 (2.19 to 15.56)	90665
Transverse myelitis	Vaccinated with ChAdOx1	1,868,6 13	119,138	<5	1.2	2.48 (0.80 to 7.69)	1038118
Transverse myelitis	Vaccinated with BNT162b2	1,661,0 35	118,647	<5	1.2	2.51 (0.81 to 7.77)	922797
Transverse myelitis	SARS-CoV-2 PCR positive test	299,203	40,596	<5	0.5	2.01 (0.28 to 14.30)	598406
Not requiring 365 da	ys observation, background	population	n anchoring	on health visit	I	1	
Bell's palsy	Vaccinated with ChAdOx1	1,955,2 34	124,509	68	50.2	1.36 (1.07 to 1.72)	109845

Bell's palsy	Vaccinated with BNT162b2	1,731,1 61	123,559	56	49.5	1.13 (0.87 to 1.47)	266332
Bell's palsy	SARS-CoV-2 PCR positive test	299,194	40,595	21	16.9	1.24 (0.81 to 1.90)	72974
Encephalomyelitis	Vaccinated with ChAdOx1	1,956,0 96	124,566	<5	2.5	1.62 (0.61 to 4.31)	1304064
Encephalomyelitis	Vaccinated with BNT162b2	1,731,9 17	123,614	<5	2.3	0.86 (0.21 to 3.43)	-5773057
Encephalomyelitis	SARS-CoV-2 PCR positive test	299,326	40,617	7	0.6	11.51 (5.49 to 24.14)	46770
Guillain Barre syndrome	Vaccinated with ChAdOx1	1,956,1 38	124,568	7	3.4	2.05 (0.98 to 4.29)	543372
Guillain Barre syndrome	Vaccinated with BNT162b2	1,731,9 11	123,614	<5	3.4	1.18 (0.44 to 3.14)	2886518
Guillain Barre syndrome	SARS-CoV-2 PCR positive test	299,321	40,617	<5	0.9	4.56 (1.71 to 12.14)	96555
Transverse myelitis	Vaccinated with ChAdOx1	1,956,1 56	124,570	<5	1.4	2.15 (0.69 to 6.66)	1222598
Transverse myelitis	Vaccinated with BNT162b2	1,731,9 36	123,615	<5	1.4	2.13 (0.69 to 6.62)	1082460
Transverse myelitis	SARS-CoV-2 PCR positive test	299,328	40,618	<5	0.6	1.60 (0.23 to 11.35)	748320
Not requiring 365 da	ays observation, background	population	n cohort of	all participar	nts followed from	1 January 2017	
Bell's palsy	Vaccinated with ChAdOx1	1,955,2 34	124,509	68	46.7	1.46 (1.15 to 1.85)	91795
Bell's palsy	Vaccinated with BNT162b2	1,731,1 61	123,559	56	45.6	1.23 (0.94 to 1.59)	166458
Bell's palsy	SARS-CoV-2 PCR positive test	299,194	40,595	21	15.1	1.39 (0.90 to 2.13)	50711
Encephalomyelitis	Vaccinated with ChAdOx1	1,956,0 96	124,566	<5	2.4	1.70 (0.64 to 4.53)	1222560
Encephalomyelitis	Vaccinated with BNT162b2	1,731,9 17	123,614	<5	2.2	0.92 (0.23 to 3.70)	-8659585
Encephalomyelitis	SARS-CoV-2 PCR positive test	299,326	40,617	7	0.5	12.96 (6.18 to 27.19)	46050

Guillain Barre syndrome	Vaccinated with ChAdOx1	1,956,1 38	124,568	7	3.2	2.20 (1.05 to 4.61)	514773
Guillain Barre syndrome	Vaccinated with BNT162b2	1,731,9 11	123,614	<5	3	1.31 (0.49 to 3.50)	1731911
Guillain Barre syndrome	SARS-CoV-2 PCR positive test	299,321	40,617	<5	0.7	5.66 (2.12 to 15.07)	90703
Transverse myelitis	Vaccinated with ChAdOx1	1,956,1 56	124,570	<5	1.2	2.42 (0.78 to 7.50)	1086753
Transverse myelitis	Vaccinated with BNT162b2	1,731,9 36	123,615	<5	1.2	2.45 (0.79 to 7.59)	962187
Transverse myelitis	SARS-CoV-2 PCR positive test	299,328	40,618	<5	0.5	2.04 (0.29 to 14.51)	598656

REFERENCE

- 1 WHO Coronavirus (COVID-19) Dashboard. https://covid19.who.int (accessed 20 Jul 2021).
- Polack FP, Thomas SJ, Kitchin N, et al. Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine. N Engl J Med 2020;383:2603–15.
- Pritchard E, Matthews PC, Stoesser N, et al. Impact of vaccination on new SARS-CoV-2 infections in the United Kingdom. *Nat Med* 2021;:1–9.
- 4 Vasileiou E, Simpson CR, Shi T, *et al.* Interim findings from first-dose mass COVID-19 vaccination roll-out and COVID-19 hospital admissions in Scotland: a national prospective cohort study. *Lancet* 2021;**397**:1646–57.
- 5 Official UK Coronavirus Dashboard. https://coronavirus.data.gov.uk/ (accessed 9 Feb 2021).
- 6 MHRA. Coronavirus vaccine weekly summary of Yellow Card reporting: Updated 6 May 2021. 2021.https://www.gov.uk/government/publications/coronavirus-covid-19-vaccine-adverse-reactions/coronavirus-vaccine-summary-of-yellow-card-reporting (accessed 7 May 2021).
- 7 Maramattom BV, Krishnan P, Paul R, *et al.* Guillain Barré Syndrome following ChAdOx1 S / nCoV 19 Vaccine. *Ann Neurol* Published Online First: 22 June 2021. doi:10.1002/ana.26143
- 8 Hasan T, Khan M, Khan F, *et al.* Case of Guillain-Barré syndrome following COVID-19 vaccine. *BMJ Case Rep* 2021;**14**:e243629.
- 9 Patel SU, Khurram R, Lakhani A, *et al.* Guillain-Barre syndrome following the first dose of the chimpanzee adenovirus-vectored COVID-19 vaccine, ChAdOx1. *BMJ Case Rep* 2021;**14**:e242956.
- 10 Theuriet J, Richard C, Becker J, *et al.* Guillain-Barré syndrome following first injection of ChAdOx1 nCoV-19 vaccine: First report. *Rev Neurol (Paris)* Published Online First: June 2021. doi:10.1016/j.neurol.2021.04.005
- 11 Introna A, Caputo F, Santoro C, et al. Guillain-Barré syndrome after AstraZeneca COVID-19-vaccination: A causal or casual association? *Clin Neurol Neurosurg* 2021;**208**:106887.
- 12 McKean N, Chircop C. Guillain-Barré syndrome after COVID-19 vaccination. *BMJ Case Rep* 2021;**14**:e244125.
- 13 Allen CM, Ramsamy S, Tarr AW, et al. Guillain Barré syndrome variant occurring after SARS CoV 2 vaccination. *Ann Neurol* Published Online First: 2 July 2021. doi:10.1002/ana.26144
- 14 Bonifacio GB, Patel D, Cook S, *et al.* Bilateral facial weakness with paraesthesia variant of Guillain-Barré syndrome following Vaxzevria COVID-19 vaccine. *J Neurol Neurosurg Psychiatry* 2021;;innp-2021-327027.

- 15 Nasuelli NA, De Marchi F, Cecchin M, *et al.* A case of acute demyelinating polyradiculoneuropathy with bilateral facial palsy after ChAdOx1 nCoV-19 vaccine. *Neurol Sci* Published Online First: 17 July 2021. doi:10.1007/s10072-021-05467-w
- 16 Min YG, Ju W, Ha Y-E, *et al.* Sensory Guillain-Barre syndrome following the ChAdOx1 nCov-19 vaccine: Report of two cases and review of literature. *J Neuroimmunol* 2021;**359**:577691.
- 17 Voysey M, Clemens SAC, Madhi SA, *et al.* Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK. *Lancet* 2021;**397**:99–111.
- 18 Knoll MD, Wonodi C. Oxford–AstraZeneca COVID-19 vaccine efficacy. *Lancet* 2021;**397**:72–4.
- 19 Vegezzi E, Ravaglia S, Buongarzone G, et al. Acute myelitis and ChAdOx1 nCoV-19 vaccine: Casual or causal association? *J Neuroimmunol* 2021;**359**:577686.
- 20 Singh Malhotra H, Gupta P, Prabhu V, *et al.* COVID-19 vaccination-associated myelitis. *QJM* Published Online First: 31 March 2021. doi:10.1093/qjmed/hcab069
- 21 Pagenkopf C, Südmeyer M. A case of longitudinally extensive transverse myelitis following vaccination against Covid-19. *J Neuroimmunol* 2021;**358**:577606.
- Waheed S, Bayas A, Hindi F, *et al.* Neurological complications of COVID-19: Guillain-Barre Syndrome following Pfizer COVID-19 vaccine. *Cureus* 2021;**13**:e13426.
- 23 Razok A, Shams A, Almeer A, et al. Post-COVID-19 vaccine Guillain-Barré syndrome; first reported case from Qatar. *Ann Med Surg (Lond)* 2021;**67**:102540.
- 24 Trimboli M, Zoleo P, Arabia G, et al. Guillain-Barré syndrome following BNT162b2 COVID-19 vaccine. Neurol Sci Published Online First: 4 August 2021. doi:10.1007/s10072-021-05523-5
- 25 Scendoni R, Petrelli C, Scaloni G, *et al.* Electromyoneurography and laboratory findings in a case of Guillain-Barré syndrome after second dose of Pfizer COVID-19 vaccine. *Hum Vaccin Immunother* 2021;:1–4.
- 26 García-Grimshaw M, Michel-Chávez A, Vera-Zertuche JM, et al. Guillain-Barré syndrome is infrequent among recipients of the BNT162b2 mRNA COVID-19 vaccine. Clin Immunol 2021;230:108818.
- 27 Vogrig A, Janes F, Gigli GL, *et al.* Acute disseminated encephalomyelitis after SARS-CoV-2 vaccination. *Clin Neurol Neurosurg* 2021;**208**:106839.
- 28 Colella G, Orlandi M, Cirillo N. Bell's palsy following COVID-19 vaccination. *J Neurol* Published Online First: 21 February 2021. doi:10.1007/s00415-021-10462-4
- 29 Gómez de Terreros Caro G, Gil Díaz S, Pérez Alé M, *et al.* Parálisis de Bell tras vacunación COVID-19: a propósito de un caso. *Neurologia* Published Online First: April 2021. doi:10.1016/j.nrl.2021.04.004

- 30 Martin-Villares C, Vazquez-Feito A, Gonzalez-Gimeno MJ, *et al.* Bell's palsy following a single dose of mRNA SARS-CoV-2 vaccine: a case report. *J Neurol* Published Online First: 25 May 2021. doi:10.1007/s00415-021-10617-3
- 31 Burrows A, Bartholomew T, Rudd J, *et al.* Sequential contralateral facial nerve palsies following COVID-19 vaccination first and second doses. *BMJ Case Rep* 2021;**14**:e243829.
- 32 Obermann M, Krasniqi M, Ewers N, *et al.* Bell's palsy following COVID-19 vaccination with high CSF antibody response. *Neurol Sci* Published Online First: 29 July 2021. doi:10.1007/s10072-021-05496-5
- 33 Iftikhar H, Noor SMU, Masood M, *et al.* Bell's palsy after 24 hours of mRNA-1273 SARS-CoV-2 vaccine. *Cureus* 2021;**13**:e15935.
- 34 Sadoff J, Le Gars M, Shukarev G, *et al.* Interim results of a phase 1-2a trial of Ad26.COV2.S Covid-19 vaccine. *N Engl J Med* 2021;**384**:1824–35.
- 35 Am ML, Kb H, Sa J, *et al.* Guillain-Barre syndrome in the placebo and active arms of a COVID-19 vaccine clinical trial: temporal associations do not imply causality. *Neurology*
- 36 Prasad A, Hurlburt G, Podury S, *et al.* A novel case of bifacial diplegia variant of guillain-Barré syndrome following Janssen COVID-19 vaccination. *Neurol Int* 2021;**13**:404–9.
- 37 Dyer O. Covid-19: Regulators warn that rare Guillain-Barré cases may link to J&J and AstraZeneca vaccines. *BMJ* 2021;**374**:n1786.
- Wolf A, Dedman D, Campbell J, et al. Data resource profile: Clinical Practice Research Datalink (CPRD) Aurum. Int J Epidemiol 2019;**48**:1740–1740g.
- 39 Herrett E, Gallagher AM, Bhaskaran K, *et al.* Data resource profile: Clinical practice research datalink (CPRD). *Int J Epidemiol* 2015;**44**:827–36.
- 40 Clinical Practice Research Datalink. CPRD GOLD June 2021. 2021. doi:10.48329/7308-XF35
- 41 Clinical Practice Research Datalink. CPRD Aurum June 2021. 2021. doi:10.48329/PYC2-WF97
- 42 Hripcsak G, Schuemie MJ, Madigan D, *et al.* Drawing reproducible conclusions from observational clinical data with OHDSI. *Yearb Med Inform* Published Online First: 21 April 2021. doi:10.1055/s-0041-1726481
- 43 Li X, Ostropolets A, Makadia R, *et al.* Characterising the background incidence rates of adverse events of special interest for covid-19 vaccines in eight countries: multinational network cohort study. *BMJ* 2021;**373**:n1435.
- Petersen I, Douglas I, Whitaker H. Self controlled case series methods: an alternative to standard epidemiological study designs. *BMJ* 2016;**354**:i4515.
- 45 Stowe J, Andrews N, Taylor B, *et al.* No evidence of an increase of bacterial and viral infections following Measles, Mumps and Rubella vaccine. *Vaccine* 2009;**27**:1422–5.

- 46 Sharples LD, Kirkwood BR. Essentials of medical statistics. *J R Stat Soc Ser A Stat Soc* 1989;**152**:263.
- 47 Sedgwick P. What is number needed to harm (NNH)? BMJ 2013;347:f4869–f4869.
- 48 Suchard MA, Simpson SE, Zorych I, *et al.* Massive parallelization of serial inference algorithms for a complex generalized linear model. *ACM Trans Model Comput Simul* 2013;**23**:1–17.
- 49 Musonda P, Farrington CP, Whitaker HJ. Sample sizes for self-controlled case series studies. *Stat Med* 2006;**25**:2618–31.
- 50 Simpson SE, Madigan D, Zorych I, et al. Multiple self-controlled case series for large-scale longitudinal observational databases. *Biometrics* 2013;**69**:893–902.
- 51 bc-coordinator. Priority list of adverse events of special interest: COVID-19. 2020.https://brightoncollaboration.us/priority-list-aesi-covid/ (accessed 11 Mar 2021).
- 52 Center for Biologics Evaluation and Research Office of Biostatistics and Epidemiology. CBER Surveillance Program Background Rates of Adverse Events of Special Interest for COVID-19 Vaccine Safety Monitoring Protocol. https://www.bestinitiative.org/wp-content/uploads/2021/02/C19-Vaccine-Safety-AESI-Background-Rate-Protocol-FINAL-2020.pdf (accessed 11 Mar 2021).
- 53 Baden LR, El Sahly HM, Essink B, et al. Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine. N Engl J Med 2021;**384**:403–16.
- 54 Repajic M, Lai XL, Xu P, *et al.* Bell's Palsy after second dose of Pfizer COVID-19 vaccination in a patient with history of recurrent Bell's palsy. *Brain Behav Immun Health* 2021;**13**:100217.
- 55 Office of the Commissioner. Coronavirus (COVID-19) Update: July 13, 2021. 2021.https://www.fda.gov/news-events/press-announcements/coronavirus-covid-19-update-july-13-2021 (accessed 20 Jul 2021).
- Tamaki A, Cabrera CI, Li S, et al. Incidence of bell palsy in patients with COVID-19. JAMA Otolaryngol Head Neck Surg Published Online First: 24 June 2021. doi:10.1001/jamaoto.2021.1266
- 57 Shemer A, Pras E, Einan-Lifshitz A, *et al.* Association of COVID-19 vaccination and facial nerve palsy: A case-control study. *JAMA Otolaryngol Head Neck Surg* Published Online First: 24 June 2021. doi:10.1001/jamaoto.2021.1259
- 58 Renoud L, Khouri C, Revol B, *et al.* Association of facial paralysis with mRNA COVID-19 vaccines: A disproportionality analysis using the world health organization pharmacovigilance database. *JAMA Intern Med* Published Online First: 27 April 2021. doi:10.1001/jamainternmed.2021.2219
- Wan EYF, Chui CSL, Lai FTT, et al. Bell's palsy following vaccination with mRNA (BNT162b2) and inactivated (CoronaVac) SARS-CoV-2 vaccines: a case series and nested case-control study. Lancet Infect Dis Published Online First: 16 August 2021. doi:10.1016/S1473-3099(21)00451-5

- 60 Toscano G, Palmerini F, Ravaglia S, *et al.* Guillain-Barré syndrome associated with SARS-CoV-2. *N Engl J Med* 2020;**382**:2574–6.
- 61 Goh Y, Beh DLL, Makmur A, et al. Pearls & Oy-sters: Facial nerve palsy in COVID-19 infection. *Neurology* 2020;**95**:364–7.
- Webb S, Wallace VC, Martin-Lopez D, *et al.* Guillain-Barré syndrome following COVID-19: a newly emerging post-infectious complication. *BMJ Case Rep* 2020;**13**:e236182.
- 63 Uncini A, Vallat J-M, Jacobs BC. Guillain-Barré syndrome in SARS-CoV-2 infection: an instant systematic review of the first six months of pandemic. *J Neurol Neurosurg Psychiatry* 2020;**91**:1105–10.
- 64 Zhao H, Shen D, Zhou H, *et al.* Guillain-Barré syndrome associated with SARS-CoV-2 infection: causality or coincidence? *Lancet Neurol* 2020;**19**:383–4.
- 65 Alberti P, Beretta S, Piatti M, *et al.* Guillain-Barré syndrome related to COVID-19 infection. *Neurol Neuroimmunol Neuroinflamm* 2020;**7**:e741.
- Gutiérrez-Ortiz C, Méndez-Guerrero A, Rodrigo-Rey S, *et al.* Miller Fisher syndrome and polyneuritis cranialis in COVID-19. *Neurology* 2020;**95**:e601–5.
- 67 Filosto M, Cotti Piccinelli S, Gazzina S, *et al.* Guillain-Barré syndrome and COVID-19: an observational multicentre study from two Italian hotspot regions. *J Neurol Neurosurg Psychiatry* 2021;**92**:751–6.
- 68 Fragiel M, Miró Ò, Llorens P, *et al.* Incidence, clinical, risk factors and outcomes of Guillain-Barré in Covid-19. *Ann Neurol* 2021;**89**:598–603.
- 69 Keddie S, Pakpoor J, Mousele C, *et al.* Epidemiological and cohort study finds no association between COVID-19 and Guillain-Barré syndrome. *Brain* 2021;**144**:682–93.
- 70 Wang Y, Wang Y, Huo L, *et al.* SARS-CoV-2-associated acute disseminated encephalomyelitis: a systematic review of the literature. *J Neurol* Published Online First: 30 August 2021. doi:10.1007/s00415-021-10771-8
- 71 Manzano GS, McEntire CRS, Martinez-Lage M, *et al.* Acute disseminated encephalomyelitis and acute hemorrhagic leukoencephalitis following COVID-19. *Neurol Neuroimmunol Neuroinflamm* 2021;**8**:e1080.
- 72 Stowe J, Andrews N, Wise L, *et al.* Investigation of the temporal association of Guillain-Barre syndrome with influenza vaccine and influenzalike illness using the United Kingdom General Practice Research Database. *Am J Epidemiol* 2009;**169**:382–8.
- 73 Grint DJ, McDonald HI, Walker JL, *et al.* Safety of inadvertent administration of live zoster vaccine to immunosuppressed individuals in a UK-based observational cohort analysis. *BMJ Open* 2020;**10**:e034886.
- 74 Li X, Lai LYH, Ostropolets A, *et al.* Bias, precision and timeliness of historical (background) rate comparison methods for vaccine safety monitoring: an empirical multi-database analysis. bioRxiv. 2021. doi:10.1101/2021.07.10.21258463

APPENDIX for

"Association between COVID-19 vaccination, infection, and risk of Guillain-Barre syndrome, Bell's palsy, encephalomyelitis and transverse myelitis: a population-based cohort and self-controlled case series analysis"

Table 1: Medical codes for outcomes.

ld	Code	Name	Vocabular
Bell's palsy			У
44784628	87651000119100	Facial palsy House-Brackmann grade VI	SNOMED
44782796	68151000119106	Facial palsy House-Brackmann grade V	SNOMED
44782795	68141000119109	Facial palsy House-Brackmann grade IV	SNOMED
44782794	68131000119100	Facial palsy House-Brackmann grade III	SNOMED
44782526	68121000119103	Facial palsy House-Brackmann grade II	SNOMED
42710044	449916008	Peripheral facial palsy	SNOMED
37396434	716243005	Sellars Beighton syndrome	SNOMED
37204553	783257005	Familial recurrent peripheral facial palsy	SNOMED
4091559	280816001	Facial palsy	SNOMED
4063208	164110008	O/E - cranial 7 -paralysis-UMN	SNOMED
4044386	230546006	Familial facial nerve palsy	SNOMED
4002030	11045000	Supranuclear facial nerve paralysis	SNOMED
3182576	1287000100000410	Partial seventh nerve palsy	Nebraska
3102370	0	Faitial Seventificative palsy	Lexicon
760893	1223966100011910	Bells palsy of right side of face	SNOMED
700000	0	Bons paloy of right side of lade	ONOMED
760892	1223962100011910	Bells palsy of left side of face	SNOMED
. 00002	0	Tomo panely or lost older or last	0
374923	193093009	Bell's palsy	SNOMED
transverse			
myelitis			
4047628	230197009	Acute viral transverse myelitis	SNOMED
4044077	230378004	Acute non-infective transverse myelitis	SNOMED
4042204	230198004	Varicella transverse myelitis	SNOMED
443904	16631009	Transverse myelopathy syndrome	SNOMED
139803	47000000	Acute transverse myelitis	SNOMED
134330	425756000	Idiopathic transverse myelitis	SNOMED
Guillain-Barré			
syndrome			
37396786	716723000	Acute inflammatory demyelinating	SNOMED
		polyradiculoneuropathy	
37396785	716722005	Acute motor sensory axonal neuropathy	SNOMED
37396086	715770009	Acute motor axonal neuropathy	SNOMED
37204541	783244002	Acute pure sensory neuropathy	SNOMED
37204369	783010003	Pharyngeal-cervical-brachial variant of	SNOMED
		Guillain-Barré syndrome	
35624130	766722008	Paraparetic variant of Guillain-Barré syndrome	SNOMED
35623634	766049000	Acute sensory ataxic neuropathy	SNOMED
4164770	40956001	Guillain-Barré syndrome	SNOMED
4070552	1767005	Fisher's syndrome	SNOMED
374925	129131007	Acute infective polyneuritis	SNOMED

encephalomyeliti s			
46285143	963741000000101	Bacterial meningoencephalomyelitis	SNOMED
43530701	182961000119101	Acute disseminated encephalomyelitis	SNOMED
		following infectious disease	
40480147	443153007	Toxic encephalomyelitis	SNOMED
36715541	721249007	Infection causing encephalomyelitis	SNOMED
36676712	773688007	Chronic lymphocytic inflammation with pontine	SNOMED
		perivascular enhancement responsive to	
		steroids	
35607947	763310000	Acute necrotizing encephalopathy of	SNOMED
		childhood	
4330496	431520004	Inflammation of spinal cord due to toxin	SNOMED
4320933	70576008	Enteroviral encephalomyelitis	SNOMED
4310021	424761009	Paraneoplastic encephalomyelitis	SNOMED
4249574	72986009	Acute hemorrhagic leukoencephalitis	SNOMED
4242575	58766009	Granulomatous meningoencephalomyelitis	SNOMED
4233538	359686005	Van Bogaert's sclerosing leukoencephalitis	SNOMED
4228612	422089004	Encephalomyelitis associated with AIDS	SNOMED
4220014	397961002	Encephalomyelitis caused by lymphocytic choriomeningitis virus	SNOMED
4206037	55234004	Pyogranulomatous meningoencephalomyelitis	SNOMED
4190307	39367000	Inflammatory disease of the central nervous system	SNOMED
4176250	50776006	Allergic encephalomyelitis	SNOMED
4147498	267576008	Encephalitis, myelitis and encephalomyelitis	SNOMED
4120303	302811004	Progressive congenital rubella	SNOMED
		encephalomyelitis	
4105201	192724008	Post mixed vaccination encephalitis	SNOMED
4105200	192711008	Post diphtheria vaccination encephalitis	SNOMED
4104690	192723002	Post hepatitis B vaccination encephalitis	SNOMED
4104546	29197009	Meningoencephalomyelitis	SNOMED
4103116	192721000	Post influenza vaccination encephalitis	SNOMED
4103115	192719005	Post mumps vaccination encephalitis	SNOMED
4103114	192718002	Post polio vaccination encephalitis	SNOMED
4103113	192716003	Post yellow fever vaccination encephalitis	SNOMED
4103112	192714000	Post rabies vaccination encephalitis	SNOMED
4103111	192712001	Post pertussis vaccination encephalitis	SNOMED
4103110	192709004	Post plague vaccination encephalitis	SNOMED
4103109	192708007	Post cholera vaccination encephalitis	SNOMED
4103108	192707002	Post paratyphoid vaccination encephalitis	SNOMED
4103107	192706006	Post typhoid vaccination encephalitis	SNOMED
4102199	192717007	Post measles vaccination encephalitis	SNOMED
4102198	192705005	Post BCG vaccination encephalitis	SNOMED
4100112	192722007	Post hepatitis A vaccination encephalitis	SNOMED
4100111	192720004	Post rubella vaccination encephalitis	SNOMED
4100110	192715004	Post typhus vaccination encephalitis	SNOMED
4100109	192713006	Post smallpox vaccination encephalitis	SNOMED
4100108	192710009	Post tetanus vaccination encephalitis	SNOMED
4098889	27040004	Experimental allergic encephalomyelitis	SNOMED
4042202	230188005	Post-influenza encephalitis	SNOMED
4035637	15316002	Simian B encephalomyelitis	SNOMED
3655306	860842004	Encephalomyelitis caused by Coxiella burnetii	SNOMED
3655305	860841006	Encephalomyelitis caused by bacterium	SNOMED

3655275	860805006	Encephalomyelitis caused by Neisseria meningitidis	SNOMED
3654623	838315004	Encephalomyelitis caused by Burkholderia	SNOMED
765827	432451000124103	Multiphasic acute disseminated encephalomyelitis	SNOMED
761989	2701000124105	Recurrent acute disseminated encephalomyelitis	SNOMED
443802	31367003	Postvaccinal encephalomyelitis	SNOMED
380322	186509002	Postvaricella encephalitis	SNOMED
379798	230199007	Post-infectious encephalomyelitis	SNOMED
379792	192704009	Post-immunization encephalitis	SNOMED
378143	45170000	Encephalitis	SNOMED
377487	111872008	Post measles encephalitis	SNOMED
375185	128191000	Rubella encephalomyelitis	SNOMED
374021	83942000	Acute disseminated encephalomyelitis	SNOMED
373189	62950007	Encephalomyelitis	SNOMED
372615	192727001	Post-infectious encephalitis	SNOMED
138965	41370002	Myelitis	SNOMED

Table 2: Power calculation for SCCS: minimum detectable relative risk

ChAdOx1

Outcome	Proportion time exposed	Proportion population exposed	Events	MDRR		
Bell's palsy	0.0346	0.9883	3456	1.2791		
Encephalomyelitis	0.0346	0.9883	251	2.2298		
Guillain Barre syndrome	0.0346	0.9883	206	2.3894		
Transverse myelitis	0.0346	0.9883	147	2.7197		

BNT162b2

Outcome	Proportion time exposed	Proportion population exposed	Events	MDRR
Bell's palsy	0.0347	0.9899	3485	1.2777
Encephalomyelitis	0.0347	0.9899	198	2.4230
Guillain Barre syndrome	0.0347	0.9899	253	2.2229
Transverse myelitis	0.0347	0.9899	98	3.2415

MDRR: minimal detectable relative risk